stoxline Quote Chart Rank Option Currency Glossary
Eli Lilly and Company (LLY)
890.1469  5.137 (0.58%)    06-18 10:34
Open: 887
High: 890.85
Volume: 408,338
Pre. Close: 885.01
Low: 884
Market Cap: 846,000(M)
Technical analysis
2024-06-18 10:20:32 AM
Short term     
Mid term     
Targets 6-month :  1042.08 1-year :  1217.16
Resists First :  892.2 Second :  1042.08
Pivot price 850.89
Supports First :  805.25 Second :  751.52
MAs MA(5) :  880.54 MA(20) :  839.65
MA(100) :  768.82 MA(250) :  639.94
MACD MACD :  27.9 Signal :  24.2
%K %D K(14,3) :  94 D(3) :  93.5
RSI RSI(14): 80
52-week High :  892.2 Low :  434.33
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LLY ] has closed below upper band by 13.7%. Bollinger Bands are 44.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 893.21 - 896.76 896.76 - 899.81
Low: 867.01 - 871.41 871.41 - 875.19
Close: 877.46 - 884.59 884.59 - 890.74
Company Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Headline News

Tue, 18 Jun 2024
Sivia Capital Partners LLC Purchases New Position in Eli Lilly and Company (NYSE:LLY) - Defense World

Tue, 18 Jun 2024
Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 15022 Shares of Stock - Defense World

Tue, 18 Jun 2024
Eli Lilly and Company's (LLY) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World

Mon, 17 Jun 2024
Eli Lilly And Alzheimer's Disease: The Paucity Of Progress (NYSE:LLY) - Seeking Alpha

Mon, 17 Jun 2024
Lilly Endowment Inc Sells 15,022 Shares of Eli Lilly and Company (NYSE:LLY) Stock - MarketBeat

Mon, 17 Jun 2024
Eli Lilly and Company (NYSE:LLY) Shares Up 0.4% - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - General
Shares Out 950 (M)
Shares Float 898 (M)
Held by Insiders 0.1 (%)
Held by Institutions 83.8 (%)
Shares Short 5,400 (K)
Shares Short P.Month 5,540 (K)
Stock Financials
EPS 6.8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 14.22
Profit Margin 17 %
Operating Margin 31.2 %
Return on Assets (ttm) 12.6 %
Return on Equity (ttm) 50.7 %
Qtrly Rev. Growth 26 %
Gross Profit (p.s.) 0
Sales Per Share 37.8
EBITDA (p.s.) 14.06
Qtrly Earnings Growth 66.4 %
Operating Cash Flow 3,680 (M)
Levered Free Cash Flow -1,230 (M)
Stock Valuations
PE Ratio 130.68
PEG Ratio 0.9
Price to Book value 62.44
Price to Sales 23.5
Price to Cash Flow 229.49
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android